AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
Reported by CNBC · cnbc.com · August 2, 2026
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
What the tape says
What to watch: This report cites a concrete figure ($400 billion) — compare it against the trailing trend before treating one data point as a turning point.
Market reaction today: $AZN +0.44%
Tone and severity are deterministic keyword classification — not a prediction, a member vote, or a recommendation. Figures are extracted from the headline as published. Wook does not republish CNBC's reporting.
Your read
Discussion
No one has weighed in yet. Start the discussion on this story.
Headline and link are attributed to CNBC. Wook of Wall Street is an independent research tool and is not affiliated with CNBC. Nothing here is financial advice or a recommendation — research and educational content only.